hereditary disease
The diagnostics subsidiary, created by Oxford Nanopore Technologies last year, plans to forge partnerships with clinical and industry partners.
Stanford researchers said the cost of their approach is in line with Illumina sequencing but did not share data on error rate and other benchmarks at this time.
The technology has been licensed by MGeneRx, which plans to commercialize it in the US first, then expand to low- and middle-income countries.
Centogene Q2 Revenues Continue to Benefit From COVID-19 Testing as Core Business Starts to Recover
The German rare disease diagnostics company had €51.9 million in Q2 revenues, significantly beating the average Wall Street estimate.
Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing
Core diagnostic testing revenues were €6.4 million, down 15 percent year over year, while pharmaceutical revenues totaled €3.6 million, down 22 percent.
Feb 25, 2021
Natera Revenues Grow 35 Percent in Q4
Jun 15, 2020
Centogene Q1 Revenues Increase 13 Percent
Jan 22, 2020
Quest Diagnostics Acquires Blueprint Genetics
Oct 3, 2019